Covid-19 vaccine Covaxin at Rs
150 not sustainable: Bharat
Covid-19 vaccine Covaxin at Rs 150 not sustainable: Bharat Biotech on Business Standard. Higher price in
private market required to offset part of the costs, argues firm
Coronavirus News Covaxin maker Bharat Biotech said on Tuesday
that the Indian government’s procurement price of Rs 150 a dose for the
Covid-19 vaccine was “non-competitive” and “not sustainable in the
long run”. Hence, it said, a higher price in the private market was
required to “offset part of the costs”.
The company’s remarks came amid questions over the differential
pricing strategy followed by vaccine manufacturers for supplies to the
government and private sector.
ALSO READ: India Coronavirus Dispatch: Scientists say didn't back
doubling vaccine gap
“If we keep supplying (Covaxin) at Rs 150 per dose, then we will no
longer be a ‘healthy’ organisation,” a senior executive of Bharat Biotech
told Business Standard.
The company has invested Rs 500 crore on Covaxin from internal
accruals, the executive said. Much of this investment has gone into
setting up new plants and re-purposing the existing plants in the past 12-
News Source : BS / Business Standard